Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

Assessing The Capacity Of Local Social Services Agencies To Respond To Referrals From Health Care Providers.

Kreuter M, Garg R, Thompson T, McQueen A, Javed I, Golla B, Caburnay C, Greer R.

Health Aff (Millwood). 2020 Apr;39(4):679-688. doi: 10.1377/hlthaff.2019.01256.

PMID:
32250682
2.

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.

Lukassen S, Lorenz Chua R, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R.

EMBO J. 2020 Apr 4. doi: 10.15252/embj.20105114. [Epub ahead of print]

PMID:
32246845
3.

[German Guideline for Idiopathic Pulmonary Fibrosis].

Behr J, Günther A, Bonella F, Dinkel J, Fink L, Geiser T, Geißler K, Gläser S, Handzhhiev S, Jonigk D, Koschel D, Kreuter M, Leuschner G, Markart P, Prasse A, Schönfeld N, Schupp JC, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2020 Mar 30. doi: 10.1055/a-1120-3531. [Epub ahead of print] German.

PMID:
32227328
4.

Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment - a German claims data analysis.

Wälscher J, Witt S, Schwarzkopf L, Kreuter M.

Respir Res. 2020 Mar 26;21(1):73. doi: 10.1186/s12931-020-01335-x.

5.

Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, Flaherty K, Funke-Chambour M, Kolb M, Kondoh Y, Maher TM, Molina Molina M, Morais A, Moor CC, Morisset J, Pereira C, Quadrelli S, Selman M, Tzouvelekis A, Valenzuela C, Vancheri C, Vicens-Zygmunt V, Wälscher J, Wuyts W, Wijsenbeek M, Cottin V, Bendstrup E.

Eur Respir J. 2020 Apr 3;55(4). pii: 1901760. doi: 10.1183/13993003.01760-2019. Print 2020 Apr.

PMID:
32060068
6.

[Test Your Knowledge].

Kreuter M, Kahn N.

Pneumologie. 2020 Feb;74(2):75-76. doi: 10.1055/a-1028-8729. Epub 2020 Feb 12. German. No abstract available.

PMID:
32050279
7.

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.

Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, Male N, Stansen W, Schoof N, Orsatti L, Swigris J.

Respir Res. 2020 Jan 30;21(1):36. doi: 10.1186/s12931-020-1298-1.

8.

A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases.

Polke M, Kirsten D, Teucher B, Kahn N, Geissler K, Costabel U, Herth FJF, Kreuter M.

Respiration. 2020;99(2):119-124. doi: 10.1159/000504677. Epub 2020 Jan 30.

PMID:
32000164
9.

Treatment of Acute Exacerbation of IPF - A Call to Arms.

Kreuter M, Maher TM.

Am J Respir Crit Care Med. 2020 Jan 24. doi: 10.1164/rccm.202001-0057ED. [Epub ahead of print] No abstract available.

PMID:
31978310
10.

Comorbidities and survival in patients with chronic hypersensitivity pneumonitis.

Wälscher J, Gross B, Morisset J, Johannson KA, Vasakova M, Bruhwyler J, Kreuter M.

Respir Res. 2020 Jan 9;21(1):12. doi: 10.1186/s12931-020-1283-8.

11.

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Valenzuela C, Torrisi SE, Kahn N, Quaresma M, Stowasser S, Kreuter M.

Respir Res. 2020 Jan 6;21(1):7. doi: 10.1186/s12931-019-1269-6. Review.

12.

Interstitial lung diseases: course report.

Kreuter M, Wells A, Mehta DR, Kovchun A.

Breathe (Sheff). 2019 Dec;15(4):270-272. doi: 10.1183/20734735.0259-2019.

13.

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.

Torrisi SE, Kahn N, Wälscher J, Sarmand N, Polke M, Lars K, Eichinger M, Heussel CP, Palmucci S, Sambataro FM, Sambataro G, Sambataro D, Vancheri C, Kreuter M.

BMC Pulm Med. 2019 Nov 12;19(1):213. doi: 10.1186/s12890-019-0937-0.

14.

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey.

Moor CC, Wijsenbeek MS, Balestro E, Biondini D, Bondue B, Cottin V, Flewett R, Galvin L, Jones S, Molina-Molina M, Planas-Cerezales L, Prasse A, Prosch H, Russell AM, Viegas M, Wanke G, Wuyts W, Kreuter M, Bonella F.

ERJ Open Res. 2019 Oct 21;5(4). pii: 00124-2019. doi: 10.1183/23120541.00124-2019. eCollection 2019 Oct.

15.

[Working Conditions and Quality of Specialized Training in Respiratory Medicine in Germany - Status quo, Challenges and Perspectives].

Bahmer T, Wälscher J, Fisser C, Kreuter M, Karg O, Böing S, Koczulla R, Raspe M.

Pneumologie. 2019 Oct;73(10):578-581. doi: 10.1055/a-1010-2863. Epub 2019 Oct 17. German. No abstract available.

PMID:
31622996
16.

Direct interplay between stereochemistry and conformational preferences in aminoacylated oligoribonucleotides.

Polyansky AA, Kreuter M, Sutherland JD, Zagrovic B.

Nucleic Acids Res. 2019 Dec 2;47(21):11077-11089. doi: 10.1093/nar/gkz902.

17.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.

Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.

18.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.

19.

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis.

Kreuter M, Lederer DJ, Cottin V, Kahn N, Ley B, Vancheri C, Weycker D, Atwood M, Kirchgaessler KU, Ryerson CJ.

Eur Respir J. 2019 Dec 12;54(6). pii: 1901188. doi: 10.1183/13993003.01188-2019. Print 2019 Dec. No abstract available.

20.

[New ways in the treatment of SSc-ILD: what makes sense?]

Kreuter M, Hoffmann-Vold AM.

Z Rheumatol. 2019 Nov;78(9):863-864. doi: 10.1007/s00393-019-00704-2. German. No abstract available.

PMID:
31485729
21.

The therapy of idiopathic pulmonary fibrosis: what is next?

Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M.

Eur Respir Rev. 2019 Sep 4;28(153). pii: 190021. doi: 10.1183/16000617.0021-2019. Print 2019 Sep 30. Review. Erratum in: Eur Respir Rev. 2019 Sep 25;28(153):.

22.

Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study.

Gannon WD, Anderson MR, Podolanczuk AJ, Kawut SM, Michos ED, Cottin V, Kreuter M, Raghu G, Barr RG, Lederer DJ.

Ann Am Thorac Soc. 2019 Nov;16(11):1451-1453. doi: 10.1513/AnnalsATS.201903-198RL. No abstract available.

PMID:
31365837
23.

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.

Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V.

Curr Med Res Opin. 2019 Nov;35(11):2015-2024. doi: 10.1080/03007995.2019.1647040. Epub 2019 Aug 2.

PMID:
31328965
24.

Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease - a prospective, randomized, multicentre cross-over trial.

Hetzel J, Eberhardt R, Petermann C, Gesierich W, Darwiche K, Hagmeyer L, Muche R, Kreuter M, Lewis R, Ehab A, Boeckeler M, Haentschel M.

Respir Res. 2019 Jul 5;20(1):140. doi: 10.1186/s12931-019-1091-1.

25.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

26.

Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey.

Powell P, Kreuter M, Wijsenbeek-Lourens M.

Breathe (Sheff). 2019 Jun;15(2):102-103. doi: 10.1183/20734735.0120-2019.

27.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M.

BMJ Open Respir Res. 2019 May 21;6(1):e000422. doi: 10.1136/bmjresp-2019-000422. eCollection 2019.

28.

Steps Toward Scalability: Illustrations From a Smoke-Free Homes Program.

Kegler MC, Haardörfer R, Melanson T, Allen L, Bundy LT, Kreuter MW, Williams RS, Hovell MF, Mullen PD.

Health Educ Behav. 2019 Oct;46(5):773-781. doi: 10.1177/1090198119848767. Epub 2019 Jun 5.

PMID:
31165637
29.

Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?

Richeldi L, Cottin V, Würtemberger G, Kreuter M, Calvello M, Sgalla G.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):261-263. doi: 10.1164/rccm.201902-0306LE. No abstract available.

PMID:
31150267
30.

Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care.

Frank AL, Kreuter M, Schwarzkopf L.

Respir Med. 2019 Jun;152:25-31. doi: 10.1016/j.rmed.2019.04.009. Epub 2019 Apr 22.

PMID:
31128606
31.

The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis.

Cottin V, Annesi-Maesano I, Günther A, Galvin L, Kreuter M, Powell P, Prasse A, Reynolds G, Richeldi L, Spagnolo P, Valenzuela C, Wijsenbeek M, Wuyts WA, Crestani B; Ariane-IPF Clinical Research Collaboration consortium.

Eur Respir J. 2019 May 23;53(5). pii: 1900539. doi: 10.1183/13993003.00539-2019. Print 2019 May. No abstract available.

PMID:
31123022
32.

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L.

Lancet Respir Med. 2019 Aug;7(8):657-664. doi: 10.1016/S2213-2600(19)30172-9. Epub 2019 May 20.

PMID:
31122893
33.

Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 May 9;53(5). pii: 1900615. doi: 10.1183/13993003.00615-2019. Print 2019 May. No abstract available.

PMID:
31072878
34.

Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.

Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V.

Chest. 2019 Oct;156(4):706-714. doi: 10.1016/j.chest.2019.04.015. Epub 2019 Apr 29.

35.

Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia: A Pilot Study in Humans.

Leibbrand M, Siefer S, Schön C, Perrinjaquet-Moccetti T, Kompek A, Csernich A, Bucar F, Kreuter MH.

J Med Food. 2019 Jun;22(6):551-559. doi: 10.1089/jmf.2018.0106. Epub 2019 Apr 24.

36.

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.

Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L.

Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7.

37.

Can monocytes predict prognosis of idiopathic pulmonary fibrosis?

Kreuter M, Maher TM.

Lancet Respir Med. 2019 Jun;7(6):467-469. doi: 10.1016/S2213-2600(19)30050-5. Epub 2019 Mar 29. No abstract available.

38.

Disseminated Mycosis by Arthrocladium fulminans Jeopardizing a Patient with GATA2 Deficiency.

Egenlauf B, Schuhmann M, Giese T, Junghanss T, Stojkovic M, Tintelnot K, de Hoog S, Greil J, Richter E, Vehresschild M, Heussel CP, Herth FJF, Kreuter M.

Respiration. 2019;97(5):472-475. doi: 10.1159/000493429. Epub 2019 Mar 29.

PMID:
30928982
39.

Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia.

Lyu Y, Boerner E, Theegarten D, Guzman J, Kreuter M, Costabel U, Bonella F.

Respiration. 2019;98(1):29-37. doi: 10.1159/000496483. Epub 2019 Mar 29.

PMID:
30928980
40.

Improving Adherence to Colorectal Cancer Screening: A Randomized Intervention to Compare Screener vs. Survivor Narratives.

McQueen A, Caburnay C, Kreuter M, Sefko J.

J Health Commun. 2019;24(2):141-155. doi: 10.1080/10810730.2019.1587109. Epub 2019 Mar 29.

41.

Specialized tobacco quitline and basic needs navigation interventions to increase cessation among low income smokers: Study protocol for a randomized controlled trial.

McQueen A, Roberts C, Garg R, Caburnay C, Fu Q, Gordon J, Bush T, Pokojski R, Thompson T, Kreuter M.

Contemp Clin Trials. 2019 May;80:40-47. doi: 10.1016/j.cct.2019.03.009. Epub 2019 Mar 20.

PMID:
30904596
42.

The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.

Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J.

Respir Res. 2019 Mar 15;20(1):59. doi: 10.1186/s12931-019-1020-3.

43.

[Acute hemoptysis and crazy-paving pattern].

Wagner WL, Rothermel A, Optazaite DE, Schneider D, Kreuter M, Kauczor HU, Heußel CP.

Med Klin Intensivmed Notfmed. 2019 Sep;114(6):558-560. doi: 10.1007/s00063-019-0554-y. Epub 2019 Feb 25. German. No abstract available.

PMID:
30805661
44.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

45.

Corrigendum to "Perceived social support in African American breast cancer patients: Predictors and effects" [Soc. Sci. Med. 192 (2017) 134-142].

Thompson T, Pérez M, Kreuter M, Margenthaler J, Colditz G, Jeffe DB.

Soc Sci Med. 2019 Feb;223:117-120. doi: 10.1016/j.socscimed.2019.01.030. Epub 2019 Feb 1. No abstract available.

46.

Social Needs and Health-Related Outcomes Among Medicaid Beneficiaries.

Thompson T, McQueen A, Croston M, Luke A, Caito N, Quinn K, Funaro J, Kreuter MW.

Health Educ Behav. 2019 Jun;46(3):436-444. doi: 10.1177/1090198118822724. Epub 2019 Jan 17.

PMID:
30654655
47.

Effect of a chamomile extract in protecting against radiation-induced intestinal mucositis.

Khayyal MT, Kreuter MH, Kemmler M, Altmann P, Abdel-Naby DH, El-Ghazaly MA.

Phytother Res. 2019 Mar;33(3):728-736. doi: 10.1002/ptr.6263. Epub 2019 Jan 10.

PMID:
30632234
48.

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study.

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2019 Mar 7;53(3). pii: 1801587. doi: 10.1183/13993003.01587-2018. Print 2019 Mar.

PMID:
30578385
49.

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.

Holtze C, Flaherty K, Kreuter M, Luppi F, Moua T, Vancheri C, Scholand MB.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31. Review.

50.

Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease.

Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, Lasitschka F, Herth FJF, Kreuter M.

Respiration. 2019;97(4):348-354. doi: 10.1159/000493428. Epub 2018 Dec 14.

PMID:
30554201

Supplemental Content

Loading ...
Support Center